Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Arthritis Research & Therapy|January 8, 2019
KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritisMark R Tanner, Michael W Pennington, Satendra S Chauhan, et al.
FEBS Letters|October 16, 2012
A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3Michael W Pennington, M Harunur Rashid, Rajeev B Tajhya, et al.
Journal of Pharmaceutical Sciences|June 18, 2016
Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal MucosaLiang Jin, Ben J Boyd, Ian C Larson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 9, 2014
Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseasesLiang Jin, Ben J Boyd, Paul J White, et al.
Marine Drugs|January 21, 2015
Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShKMichael W Pennington, Shih Chieh Chang, Satendra Chauhan, et al.
Toxicon : Official Journal of the International Society on Toxinology|June 5, 2012
Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteriaShih Chieh Chang, Charles A Galea, Eleanor W W Leung, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 18, 2018
Targeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid ArthritisMark R Tanner, Michael W Pennington, Brayden H Chamberlain, et al.
Pageof 6